Clinical Trials
11 trialsNCT05890742 2026-05-28
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Active not recruiting
NCT03607539 2026-05-11
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT06497985 2026-03-19
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT05116462 2025-06-26
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Active not recruiting
NCT06584032 2025-01-07
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
Phase 3 Recruiting
NCT03802240 2023-11-27
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03150875 2023-02-28
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03629925 2023-02-28
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed